Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY25 results · Apr–Jun 2024
Sun Pharma Advanced Research Company reported revenue from operations of ₹16.81 crore and net loss of ₹95.90 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 16.81 | — | — | 16.56 | +1.5% |
| Other income | 1.56 | — | — | 4.40 | −64.5% |
| Total income | 18.37 | — | — | 20.96 | −12.4% |
| Profit before tax | (95.50) | — | — | (105.41) | Loss narrowed |
| Net profit for the period | (95.90) | — | — | (105.79) | Loss narrowed |
| EPS, basic (₹) | (2.96) | — | — | (3.26) | Loss narrowed |
| Net margin (%) | -570.5 | — | -638.8 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 16.81 | 23.95 | −29.8% | 16.56 | +1.5% |
| Other income | 1.56 | 10.19 | −84.7% | 4.40 | −64.5% |
| Total income | 18.37 | 34.14 | −46.2% | 20.96 | −12.4% |
| Profit before tax | (96.84) | (95.35) | Loss widened | (106.69) | Loss narrowed |
| Net profit for the period | (96.84) | (95.35) | Loss widened | (106.69) | Loss narrowed |
| EPS, basic (₹) | (2.98) | (2.94) | Loss widened | (3.29) | Loss narrowed |
| Net margin (%) | -576.1 | -398.1 | -644.3 |
Consolidated
- Filed with BSE
- 06 Aug 2024, 10:32 IST
- Board meeting
- 05 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2024, 10:32 IST
- Board meeting
- 05 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE